Release studies were
performed with a tablet formulation of the ASD to circumvent wetting
issues with the ASD powder. The tablet (75 mg) contained ASD powder
(equivalent to 5 mg DLM) mixed with excipients (sodium starch glycolate,
4 mg; croscarmellose sodium, 4 mg; silica colloidal hydrate, 0.6 mg;
magnesium stearate, 0.6 mg; Avicel PH 101, q.s. 75 mg).
15 (link) Release testing was conducted at 150 rpm, 37
°C, using a USP apparatus II (Hanson, Billerica, MA). Release
studies were performed in a single-stage medium (phosphate buffer,
pH 6.5) or using pH shift experiments, with the first dissolution
stage at an acidic pH (0.02 M HCl solution, pH 1.6, or phosphate buffer
at pH 3.0 or pH 5.0) for 60 min, followed by dissolution in phosphate
buffer pH 6.5 for an additional 30 min. The low pH media were converted
to pH 6.5 by adding concentrated phosphate buffer pH 7.3, the composition
of which is presented in
Table 2. The dose concentration in the dissolution medium was 100
μg/mL.
Drug release as a function of time was determined
using an in situ
dissolution monitoring system (Pion Rainbow Instrument, Billerica,
MA) based on fiber optic UV spectroscopy. Drug concentration was calculated
from analysis of second derivative spectra by determining the area
under the curve over the wavelength range of 330–350 nm. Calibration
curves of DLM in different buffers were built over the concentration
range of 1–100 μg/mL.
Polymer release was evaluated
at different time points by withdrawing
1.5 mL of dissolution medium, which was replaced with fresh media,
followed by centrifugation at 14,800 rpm, 37 °C for 3 min to
remove undissolved ASDs. Polymer concentration was determined by the
HPLC-ELSD method as described above.
Nguyen H.T., Van Duong T, & Taylor L.S. (2023). Impact of Gastric pH Variations on the Release of Amorphous Solid Dispersion Formulations Containing a Weakly Basic Drug and Enteric Polymers. Molecular Pharmaceutics, 20(3), 1681-1695.